EVast Bio is a US-based, clinical-stage biotech born as a result of ground-breaking work at C4C (https://c4c.cl). EVast is devoted to unlocking the vast potential of Extracellular Vesicles (EVs) as therapeutics and delivery systems.
Company Details
- Founded
- 2024
- Address
- Delaware, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://evast.bio
- Keywords
- Exosomes, Extracellular Vesicles, Drug Delivery, Therapeutics, Cell and Gene Therapy, Biotech, Orthopedics, Oncology, Inflammatory diseases, Non-viral Vectors, Nanotechnology, Biologics, Advanced Therapies, Age-related diseases, Longevity.
- HQ
- Delaware
Evast Bio Inc. Questions
Evast Bio Inc.'s website is https://evast.bio
Evast Bio Inc.'s LinkedIn profile is https://www.linkedin.com/company/evastbio
Evast Bio Inc.'s industry is
Biotechnology Research
Evast Bio Inc.'s top competitors are
Versatope Therapeutics,
Vexxel,
Phio Pharmaceuticals Corp.,
Impact Center Of Interventional Medicine For Precision And Advanced Cellular Therapy,
Stealth Startup,
Foundation For Angelman Syndrome Therapeutics,
Exogenus Therapeutics,
Nalca Biotech,
Regeneron,
Cells For Cells.
Evast Bio Inc.'s categories are Biotechnology Research
Evast Bio Inc.'s founding year is 2024
